31 May 2016 07:00
TOTAL VOTING RIGHTS
VERNALIS PLC (the "Company")
31 May 2016
Vernalis plc (LSE: VER) announces that for the purposes of the Disclosure and Transparency Rules, the Company's total issued share capital at the date of this announcement is 526,054,688 ordinary shares of 1p each, with one voting right per share. There are no shares held in treasury.
The total number of voting rights in the Company is therefore 526,054,688.
The above figure of 526,054,688 shares may be used by shareholders as a denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, the Company, under the Disclosure and Transparency Rules.
- Ends -
Enquiries:
Vernalis plc: | +44 (0) 118 938 0015 |
Ian Garland, Chief Executive Officer | |
David Mackney, Chief Financial Officer
| |
Canaccord Genuity Limited (Nominated Adviser): | +44 (0) 20 7523 8000 |
Dr Julian Feneley | |
Henry Fitzgerald-O'Connor | |
Rupert Winckler | |
Emma Gabriel
| |
Shore Capital (Joint Broker): | +44 (0) 20 7408 4090 |
Bidhi Bhoma | |
Toby Gibbs
| |
FTI Consulting: | +44 (0) 20 3727 1000 |
Ben Atwell Simon Conway Stephanie Cuthbert |
Notes to Editors
About Vernalis
Vernalis is a revenue generating, commercial stage pharmaceutical company with significant expertise in drug development. The Group has three approved products: Tuzistra® XR targeting the US prescription cough-cold market; Moxatag®, a once-a-day formulation of the antibiotic, amoxicillin, indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatric patients 12 years and older; and frovatriptan for the acute treatment of migraine. It has an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough-cold market as well as eight programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including Asahi Kasei Pharma, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier, Taisho, and Tris.
For further information about Vernalis, please visit www.vernalis.com.